ORMP — ORAMED PHARMACEUTICALS INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1176309 ·
Last close
$4.73
Market Cap
$196.76M
52W High
$5.47
52W Low
$1.95
ADV30
222,990
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | 0 | -2,766,000 | 78,156,000 | 369,643,000 | 15,245,000 | 52,170,000 |
| Mar 2026 | 0 | 0 | -3,659,000 | 38,310,000 | 268,847,000 | 13,202,000 | 30,571,000 |
| Dec 2025 | 0 | 0 | -5,672,000 | 10,009,000 | 230,864,000 | 45,947,000 | 31,120,000 |
| Sep 2025 | 0 | 0 | -2,427,000 | 48,395,000 | 220,493,000 | 52,179,000 | 18,163,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-8,541,000
Investing CF
$-37,661,000
Financing CF
$-15,105,000
CapEx
$-2,140,000
Dividends Paid
$-10,364,000
Buybacks
$-5,563,000
EPS Diluted TTM
$2.16
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-85,121,000
Inventory
—
Receivables
$0
ST Investments
$52,638,000
EBIT TTM
$78,723,000
Pretax Income TTM
$131,822,000
Interest Exp TTM
$2,558,000
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
$-14,402,000
Free Cash Flow
$2,511,500
Enterprise Value
$143,964,672
Total Cash
$50,612,000
Total Debt
$733,000
Shares Out
41,597,354
Trailing EPS
$4.13
Book Value
$7.68
ROE
74.2%
ROA
-3.4%
Div Yield
5.36%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,000,000 | -15,088,000 | 64,050,000 | 230,864,000 | 31,120,000 | 199,744,000 | -9,145,000 |
| Dec 2024 | 0 | -12,781,000 | -19,060,000 | 155,278,000 | 9,931,000 | 146,265,000 | -8,412,000 |
| Dec 2023 | 1,340,000 | -15,769,000 | 5,525,000 | 220,551,000 | 57,658,000 | 163,821,000 | -10,295,000 |
| Dec 2022 | 2,703,000 | -40,598,000 | -36,561,000 | 161,642,000 | 10,486,000 | 151,812,000 | -27,918,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.08
Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)
max pain strike: $5.00 · spot: $4.76 · call volume: 5 · put volume: 31
Expected Move to 2026-11-20:
±$0.73
(15.23%) —
implied range
$4.04 –
$5.49
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ADAG | Adagene Inc. | $196.73M | $2.93 | — |
| NKTX | Nkarta, Inc. | $196.97M | $2.75 | — |
| VRXA | Veraxa Biotech AG - Post de-SPAC | $199.39M | $1.41 | — |
| BCYC | BICYCLE THERAPEUTICS PLC | $186.29M | $3.68 | — |
| FHTX | Foghorn Therapeutics Inc. | $207.85M | $3.50 | — |
News headlines (Yahoo Finance, 1h cache)
ORMP: Investment Gains Contributed to Strong 2Q26 EPS, While Inclusion in Russell Indexes Arguably Boosts Awareness
2026-08-28 09:30 · Yahoo
ORMP: View Inclusion in Russell Indexes as Positive That Could Raise Awareness in Investment Community
2026-06-18 12:21 · Yahoo
Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes
2026-06-17 12:55 · Yahoo
Oramed Pharmaceuticals And Two Other Promising Penny Stocks For Savvy Investors
2026-04-14 18:06 · Yahoo
Lifeward Publishes Updated Investor Presentation Highlighting Commercial Growth Strategy
2026-09-08 12:30 · Yahoo
ORMP: Strategically Acquiring Interests in Medtech & Technology Companies
2026-06-08 13:08 · Yahoo
Nano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation Committee
2026-08-17 12:00 · Yahoo
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet
2026-06-25 15:35 · Yahoo
June 2026 Penny Stocks To Watch For Potential Growth
2026-06-15 18:05 · Yahoo
Spotlight On Oramed Pharmaceuticals And Two Other Prominent Penny Stocks
2026-05-13 12:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.